EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Basilea Pharmaceutica EBITDA Margin % Related Terms
Basilea Pharmaceutica EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PK5 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (FRA:PK5) has a EBITDA Margin % of 22.43% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #145 out of 944 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Basilea Pharmaceutica's EBITDA Margin % too high?
Basilea Pharmaceutica's current EBITDA Margin % is 22.43%. Based on the distribution chart, Basilea Pharmaceutica ranks #145 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #145 out of 944 companies for EBITDA Margin %. This places Basilea Pharmaceutica in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current EBITDA Margin % is 22.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (FRA:PK5) is currently considered Fairly Valued. The stock's GF Value™ is €60.85, compared to a current price of €56.30 — trading 7.5% below its estimated fair value. The current EBITDA Margin % is 22.43%. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Basilea Pharmaceutica (FRA:PK5), the current EBITDA Margin % is 22.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of €56.30 is trading 7.5% below its estimated GF Value™ of €60.85.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for FRA:PK5:
EBITDA Margin %: 22.43%
GF Value™: €60.85 vs. price of €56.30 (7.5% below fair value)
No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for FRA:PK5
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PK5 has been successfully added to your 
